wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q49873786-5F27D77F-B1B5-4403-BEA3-1AEF80C55B2F
Q49873786-5F27D77F-B1B5-4403-BEA3-1AEF80C55B2F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49873786-5F27D77F-B1B5-4403-BEA3-1AEF80C55B2F
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States.
P2860
Q49873786-5F27D77F-B1B5-4403-BEA3-1AEF80C55B2F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49873786-5F27D77F-B1B5-4403-BEA3-1AEF80C55B2F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d140ac3ce4a7820420d8a377775ea317dd5b49c8
P2860
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.